Sign up to our newsletter Subscribe
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
Value, Affordability and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
